| Literature DB >> 31674322 |
Rengaswamy Sankaranarayanan1, Partha Basu2, Prabhdeep Kaur3, Rajesh Bhaskar4, Gurinder Bir Singh4, Phumzay Denzongpa5, Rajesh K Grover6, Paul Sebastian7, Tapan Saikia8, Kunal Oswal7, Rishav Kanodia7, Amantia Dsouza7, Ravi Mehrotra9, Goura Kishor Rath10, Viniita Jaggi6, Sundram Kashyap6, Ishu Kataria11, Roopa Hariprasad9, Peter Sasieni12, Neerja Bhatla13, Preetha Rajaraman14, Edward L Trimble15, Soumya Swaminathan16, Arnie Purushotham17.
Abstract
Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in Andhra Pradesh and Gujarat in 2009 introduced HPV vaccination in public health services in India. Following a few deaths in these projects, although subsequently deemed unrelated to vaccination, HPV vaccination in research projects was suspended. This suspension by default resulted in some participants in a trial evaluating two versus three doses receiving only one dose. Since 2016, the successful introduction of HPV vaccination in immunisation programmes in Punjab and Sikkim (with high coverage and safety), government-sponsored opportunistic vaccination in Delhi, prospects of a single dose providing protection, and future availability of an affordable Indian vaccine shows promise for future widespread implementation and evaluation of HPV vaccination in India.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31674322 DOI： 10.1016/S1470-2045(19)30531-5
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316